Biased epitope selection by recombinant vaccinia-virus (rVV)-infected mature or immature dendritic cells

Gene Therapy

Volumn 10, Issue 20, 2003, Pages 1754-1765

  Nagorsen, D ^a,b   Panelli, M ^a   Dudley, M E ^c   Finkelstein, S E ^c   Rosenberg, S A ^c   Marincola, F M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UKBF   (Germany)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antigen; CTL; Dendritic cells; Epitopes; MHC; Vaccinia virus

Indexed keywords

CELL MARKER; CYTOKINE; GLYCOPROTEIN GP 100; HLA A ANTIGEN; HLA ANTIGEN CLASS 2; MELANOMA ANTIGEN; RECOMBINANT VACCINE; VIRUS VECTOR;

ACTIVE IMMUNIZATION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; BINDING AFFINITY; CELL MATURATION; CELL SELECTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; EXPRESSION VECTOR; GENE CONSTRUCT; GENETIC CODE; HLA SYSTEM; HUMAN; HUMAN CELL; MONONUCLEAR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVIEW; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS INFECTION; VIRUS RECOMBINANT; WILD TYPE;

ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CLONE CELLS; DENDRITIC CELLS; EPITOPES; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; RECEPTORS, ANTIGEN, T-CELL; VACCINIA VIRUS;

DNA VIRUSES; VACCINIA VIRUS; VECTORS;

EID: 0141851075     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302066     Document Type: Review

References (63)

1. Bhardwaj N, Friedman SM, Cole BC, Nisanian AJ. Dendritic cells are potent antigen-presenting cells for microbial superantigens. J Exp Med 1992; 175: 267-273.
2. Bhardwaj N. Processing and presentation of antigen by dendritic cells: implications for vaccines. Trends Mol Med 2001; 7: 388-394.
3. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89.
4. Fontaneau JF, Larsson M, Bhardwaj N. Dendritic cell-dead-cell interactions: implications and relevance for immunotherapy. J Immunother 2001; 24: 294-304.
5. Bronte V et al. Antigen expression by dendritic cell correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA 1997; 94(7): 3183-3188.
6. Bhardwaj N et al. Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells. J Clin Invest 1994; 94: 797-807.
7. Kim CJ et al. Dendritic cells infected with poxviruses encoding MART-1/MelanA sensitize T lymphocytes in vitro. J Immunother 1997; 20: 276-286.
8. Kim CJ et al. Use of recombinant poxviruses to stimulate anti-melanoma T cell reactivity. Ann Surg Oncol 1998; 5: 64-76.
9. Schutz A et al. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/MelanA antigen. Cancer Gene Ther 2001; 8: 655-661.
10. Sette A et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 1994; 153: 5586-5592.
11. Kawakami Y et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347-352.
12. Kawakami Y et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 1995; 154: 3961-3968.
13. Parkhurst MR et al. Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201 binding residues. J Immunol 1996; 157: 2539-2548.
14. Valmori D et al. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide. J Immunol 1998; 161: 6956-6962.
15. Rivoltini L et al. A superagonist variant of peptide MART-1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implications for more effective immunotherapy. Cancer Res 1999; 59: 301-306.
16. Valmori D et al. Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. Int Immunol 1999; 11: 1971-1980.
17. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 1996; 56: 4749-4757.
18. Rosenberg SA et al. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998; 4: 321-327.
19. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T-cells. Immunity 1998; 8: 89-95.
20. Lanzavecchia A, Iezzi G, Viola A. From TCR engagement to T-cell activation: a kinetic view of T cell behavior. Cell 1999; 96: 1-4.
21. Larsson M et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol 2000; 165: 1182-1190.
22. Steinman RM & Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer 2001; 94: 459-473.
23. Jonuleit H et al. A comparison of two types of dendritic cells as adjuvants for the induction of melanoma-specific T cell responses in humans following intranodal injection. Int J Cancer 2001; 93: 243-251.
24. Engelmayer J et al. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999; 163: 6762-6768.
25. Smith GL et al. Vaccinia virus immune evasion. Immunol Rev 1997; 159: 137-154.
26. Tsujisaki M et al. Fine specificity and idiotype diversity of the murine anti-HLA-A2, A28 monoclonal antibodies CR11-351 and KS1. Transplantation 1988; 45: 632-639.
27. Bettinotti M et al. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J Immunol 1998; 161: 877-889.
28. Nielsen MB et al. Status of activation of circulating vaccine-elicited CD8+ T cells. J Immunol 2000; 165: 2287-2296.
29. Monsurro' V et al. Functional heterogeneity of vaccine-induced CD8+ T cells. J Immunol 2002; 168: 5933-5942.
30. Dudley ME et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother 2001; 24: 363-373.
31. Dudley ME, Nishimura MI, Holt AKC, Rosenberg SA. Anti-tumor immunization with a minimal peptide epitope (G9-209-2M) leads to a functionally heterogeneous CTL response. J Immunother 1999; 22: 288-298.
32. Lee KH et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999; 163: 6292-6300.
33. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell [see comments]. Nature 1998; 393: 474-478.
34. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 1249-1255.
35. Lapointe R et al. Retrovirally transduced human dendritic cells can generate T cells recognizing multiple MHC class I and class II epitopes from the melanoma antigen glycoprotein 100. J Immunol 2001; 167: 4758-4764.
36. Parmiani G et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002; 94: 805-818.
37. Kim CJ, Parkinson DR, Marincola FM. Immunodominance across the HLA polymorphism: implications for cancer immunotherapy. J Immunother 1997; 21: 1-16.
38. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000; 74: 181-273.
39. Ferrone S, Marincola FM. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 1995; 16: 487-494.
40. Rosenberg SA et al. Immunization of patients with metastatic melanoma using recombinant adenoviruses encoding the MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 1998; 90: 1894-1899.
41. Restifo NP, Rosenberg SA. Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol 1999; 11: 50-57.
42. Coller HA et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling and adhesion. Proc Natl Acad Sci USA 2000; 28: 3260-3265.
43. Wang R et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 2001; 98: 10817-10822.
44. Janetzki S et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: a pilot study. Int J Cancer 2000; 88: 232-238.
45. Hsueh EC et al. Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma. Ann Surg Oncol 2002; 9: 486-492.
46. Shiku H et al. Development of a cancer vaccine: peptides, proteins and DNA. Cancer Chemother Pharmacol 2000; 46: S77-S82.
47. Kirk CJ, Mule JJ. Gene-modified dendritic cells for use in tumor vaccines. Hum Gene Ther 2000; 11: 797-806.
48. Yang S et al. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. J Immunol 2000; 164: 4204-4211.
49. Prabakaran I et al. Mature CD83(+) dendritic cells infected with recombinant gp100 vaccinia virus stimulate potent antimelanoma T cells. Ann Surg Oncol 2002; 9: 411-418.
50. Smith SG et al. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T cell responses. Clin Cancer Res 2001; 7: 4253-4261.
51. Cella M et al. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T-cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752.
52. Monsurro V et al. Kinetics of TCR use in response to repeated epitope-specific immunization. J Immunol 2001; 166: 5817-5825.
53. Granucci F et al. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat Immunol 2001; 2: 882-888.
54. Andrews DM et al. Infection of dendritic cells by murine cytomegalovirus induces functional paralysis. Nat Immunol 2001; 2: 1077-1084.
55. Sauter B et al. Consequences of cell death: exposure to necrotic tumor cells, but no primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 434.
56. Larsson M et al. Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 2001; 31: 3432-3442.
57. Sercarz EE et al. Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 1993; 11: 729-766.
58. Niedermann G et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules. Immunity 1995; 2: 289-299.
59. Valmori D et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 2000; 164: 1125-1131.
60. Speiser DE et al. In vivo activation of melanoma-specific CD8(+)T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells. Eur J Immunol 2002; 32: 731-741.
61. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendrilic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and down-regulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109-1118.
62. Lapointe R et al. Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes. Eur J Immunol 2000; 30: 3291-3298.
63. Cormier JN et al. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998; 75: 517-524.